Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
A shareholder filed a Rule 144 notice to sell 9,748 common shares, with an aggregate market value of $64,141.84, through Fidelity Brokerage Services on the NASDAQ market. The shares relate to stock options that were granted on January 9, 2020 and May 11, 2020 and were acquired and paid for in cash on January 16, 2026.
Over the prior three months, the same seller, Erica Rogers, reported additional common stock sales, including 20,000 shares for $172,804.00 on December 29, 2025 and 20,000 shares for $132,034.00 on January 15, 2026, along with two smaller transactions. The filer certifies they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder filed a Form 144 notice to sell 20,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 132,034.24.
The filing states that 52,871,731 shares of this class were outstanding and that the planned sale is expected around 01/15/2026.
The 20,000 shares come from stock options granted on 01/09/2020 and 05/11/2020, each for 10,000 shares, acquired and paid for in cash on 01/15/2026. Over the prior three months, Erica Rogers sold additional blocks of common stock totaling 40,252 shares, with gross proceeds of 172,804.00, 84,223.26, and 73,781.00.
Sight Sciences, Inc. filed a current report to let investors know it has released preliminary, unaudited financial results. On January 13, 2026, the company issued a press release with selected results for the fourth quarter and full year ended December 31, 2025. That press release is included as Exhibit 99.1 to this Form 8-K under the section covering results of operations and financial condition. The company states that this information, including the exhibit, is being furnished rather than filed, which limits how it is treated under securities law and how it may be incorporated into other SEC filings.
SGHT filed a notice under Rule 144 for a planned sale of 10,000 shares of common stock through Fidelity Brokerage Services LLC on 01/12/2026, listed with an aggregate market value of 73,781.43 and referencing 52,871,731 shares outstanding and NASDAQ as the exchange.
The shares to be sold were acquired on 01/12/2026 via an option originally granted on 05/11/2020, with cash as the form of payment. The notice lists prior sales for the same account holder, Erica Rogers, including 20,000 common shares sold on 12/29/2025 for gross proceeds of 172,804.00 and 10,252 common shares sold on 12/30/2025 for gross proceeds of 84,223.26. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
Sight Sciences, Inc. insider activity: President, CEO, director and 10% owner Paul Badawi reported two sales of the company’s common stock. On January 2, 2026, he sold 25,356 shares at a weighted average price of $7.43 per share, and on January 6, 2026, he sold 11,870 shares at a weighted average price of $7.48 per share.
According to the footnotes, the January 2 sale reflects shares sold to cover his tax liability arising from the vesting of restricted stock units. Both trades were executed in multiple transactions within disclosed price ranges. After these transactions, Badawi beneficially owned 5,925,276 shares of Sight Sciences common stock directly.
Sight Sciences Chief Operating Officer Alison Bauerlein reported two open-market sales of company common stock. On January 5, 2026, she sold 10,896 shares at a weighted average price of $7.82 per share, and on January 6, 2026, she sold 9,647 shares at a weighted average price of $7.48 per share.
According to the footnotes, these sales were made to cover her tax liability arising from the vesting of restricted stock units, meaning they were linked to equity compensation rather than a discretionary reduction in holdings. After these transactions, she beneficially owned 599,983 shares of Sight Sciences common stock directly.
Sight Sciences executive Brenton Taylor, EVP of Operations & R&D, reported a small sale of company stock mainly to cover taxes from vesting equity. On January 6, 2026, he sold 619 shares of Sight Sciences common stock at a weighted average price of $7.48 per share, through multiple trades priced between $7.39 and $7.67. After this tax-related sale, he directly holds 170,212 shares of the company’s common stock.
Sight Sciences insider Jeremy Hayden has filed a notice of proposed stock sales under Rule 144. The filing states an intention to sell 1,785 shares of Sight Sciences common stock through Fidelity Brokerage Services on the NASDAQ, with an approximate sale date of January 6, 2026 and an aggregate market value of $13,354.66. These shares were acquired on January 2, 2026 via restricted stock vesting from the issuer as compensation.
The notice also lists recent sales over the prior three months by the same seller, including 3,150 shares sold on November 12, 2025 for gross proceeds of $25,227.78, 44,850 shares sold on November 25, 2025 for $362,596.77, and 9,385 shares sold on January 5, 2026 for $73,418.85. The Rule 144 representation confirms the seller states they are not aware of undisclosed material adverse information about the company.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 13,958 shares of common stock on 12/16/2025 at a weighted average price of $8.308 per share. The shares were bought in multiple trades at prices ranging from $8.12 to $8.40.
After this transaction, Encrantz directly beneficially owns 1,391,922 shares, which include 30,952 restricted stock units subject to vesting. He is also reported as having indirect beneficial ownership of 632,456 shares held by a revocable trust where he serves as trustee, and 5,086,920 shares held by Allegro Investment Fund, L.P., although he disclaims pecuniary interest and beneficial ownership in the Allegro-held shares.
Sight Sciences, Inc. (SGHT) reported an insider transaction by its EVP, Operations & R&D, Brenton Taylor. On 11/17/2025, Taylor sold 14,418 shares of common stock at a weighted average price of $7.06 per share. According to the footnotes, the sale was made to cover his tax liability arising from the vesting of restricted stock units. After this transaction, Taylor beneficially owned 170,831 shares of Sight Sciences common stock.